**Author details**

Makmur Sitepu\* and Jusuf Rachmadsyah Department of Obstetric and Gynecology, Medical Faculty, Universitas Sumatera Utara, Medan, Indonesia

\*Address all correspondence to: makmurstp@gmail.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**31**

*Risk Factor and Biomarker of Preeclampsia DOI: http://dx.doi.org/10.5772/intechopen.85173*

[11] Kusanovic JP, Romero R,

Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine. 2009;**22**(11):1021-1038

[12] Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. Journal of the American Society of Nephrology. 2007;**18**(8):2281-2284

[13] Rolfo A, Many A, Racano A, et al. Abnormalities in oxygen sensing define early and late onset preeclampsia as distinct pathologies. PLoS One.

[14] Banks RE, Forbes MA, Searles J, et al. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Molecular Human Reproduction. 1998;**4**(4):377-386

[15] Verheul HMW, Pinedo HM. Possible

[16] Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. American Journal of Obstetrics & Gynecology. 2012;**206**(1):58.e1-58.e8

[17] Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;**125**(7):911-919. (PMC free article)

[18] Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: A longitudinal study of women with chronic hypertension

molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer.

2010;**5**(10):e13288

2007;**7**(6):475-485

[1] Villar K. Eclampsia and preeclampsia: A health problem for 2000 years. In: Critchley H, MacLean A, Poston L, editors. Preeclampsia. London, UK: RCOG Press; 2003. pp. 189-207

[2] Noris M, Perico N, Remuzzi G. Mechanisms of disease: Pre-eclampsia. Nature Clinical Practice Nephrology.

[3] Barker DJP, Osmond C, Forsen TJ, Kajantie E, Eriksson JG. Maternal and social origins of hypertension. Hypertension. 2007;**50**(3):565-571

programming of adult disease. Molecular Medicine Today. 1995;**1**(9):418-423

[5] Godfrey KM, Inskip HM, Hanson MA.

development on growth and metabolism. Seminars in Reproductive Medicine. 2011;**29**(3):257-265. (PMC free article)

[6] Cross JC, Baczyk D, Dobric N, et al. Genes, development and evolution of the placenta. Placenta. 2003;**24**(2-3):123-130

[7] Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. The Lancet. 2001;**357**(9249):53-56

[8] Redman CW, Sargent IL. Latest

[9] Winn VD, Gormley M, Fisher SJ. The impact of preeclampsia on gene expression at the maternal-fetal interface. Pregnancy Hypertension. 2011;**1**(1):100-108. (PMC free article)

[10] Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. Journal of Clinical Investigation. 1993;**91**(3):950-960

advances in understanding preeclampsia. Science. 2005;**308**(5728):1592-1594

The long-term effects of prenatal

[4] Barker DJP. Intrauterine

2005;**1**(2):98-120

**References**

*Risk Factor and Biomarker of Preeclampsia DOI: http://dx.doi.org/10.5772/intechopen.85173*
